Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

News Release

Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

September 10, 2020 at 4:25 PM EDT

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences 
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contacts:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Graham Morrell
781-686-9600
gmorrell@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com


WAVE LOGO NEW COLOR SWOOSH.jpg

Source: Wave Life Sciences USA, Inc.